Purple Biotech Ltd.
Symbol: PPBT
NASDAQ
0.67
USDMarket price today
-0.6555
P/E Ratio
0.0000
PEG Ratio
17.38M
MRK Cap
- 0.00%
DIV Yield
Purple Biotech Ltd. (PPBT) Financial Statements
Balance Sheet
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 73.01 | 15.4 | 32.1 | 47.2 | |||||||||||
balance-sheet.row.short-term-investments | 4.34 | 0.9 | 17.1 | 36.3 | |||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-current-assets | 3.29 | 0.4 | 1.1 | 1.3 | |||||||||||
balance-sheet.row.total-current-assets | 76.3 | 15.8 | 33.3 | 48.5 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 2.18 | 0.5 | 0.7 | 0.9 | |||||||||||
balance-sheet.row.goodwill | 112.06 | 28 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0.11 | 0 | 20.7 | 20.5 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 112.18 | 28 | 20.7 | 20.5 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0.2 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 0.2 | |||||||||||
balance-sheet.row.total-non-current-assets | 114.36 | 28.5 | 21.4 | 21.7 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 190.66 | 44.3 | 54.6 | 70.2 | |||||||||||
balance-sheet.row.account-payables | 10.15 | 3.5 | 2.1 | 1.5 | |||||||||||
balance-sheet.row.short-term-debt | 0.74 | 0.2 | 0.2 | 0.2 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 0.87 | 0.2 | 0.3 | 0.6 | |||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 13.01 | 3.5 | 4.7 | 2.6 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 3.95 | 2.8 | 0.5 | 0.8 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 1.42 | 0.2 | 0.5 | 0.7 | |||||||||||
balance-sheet.row.total-liab | 27.85 | 10 | 7.5 | 5.1 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.retained-earnings | -520.12 | -137.5 | -117.6 | -95.9 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 69.19 | 38.5 | 10.1 | 8.8 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 613.23 | 133.2 | 154.4 | 152 | |||||||||||
balance-sheet.row.total-stockholders-equity | 162.29 | 34.2 | 46.9 | 64.8 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 190.66 | 44.3 | 54.6 | 70.2 | |||||||||||
balance-sheet.row.minority-interest | 0.51 | 0.1 | 0.2 | 0.3 | |||||||||||
balance-sheet.row.total-equity | 162.81 | 34.3 | 47.1 | 65.1 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 190.66 | - | - | - | |||||||||||
Total Investments | 4.34 | 0.9 | 17.1 | 36.5 | |||||||||||
balance-sheet.row.total-debt | 1.61 | 0.4 | 0.5 | 0.7 | |||||||||||
balance-sheet.row.net-debt | -67.07 | -14.1 | -14.5 | -10.1 |
Cash Flow Statement
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -19.95 | -19.9 | -21.8 | -17.8 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0.2 | 0.2 | 0.2 | 0.2 | |||||||||||
cash-flows.row.deferred-income-tax | 0.64 | -0.8 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 1.88 | 1.9 | 2.4 | 2.1 | |||||||||||
cash-flows.row.change-in-working-capital | 0.27 | 0.3 | 3.3 | 0.6 | |||||||||||
cash-flows.row.account-receivables | 0 | 0.2 | 0.3 | -0.3 | |||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0.6 | |||||||||||
cash-flows.row.account-payables | 1.33 | 1.3 | 0.8 | 0.3 | |||||||||||
cash-flows.row.other-working-capital | -1.06 | -1.2 | 2.1 | 0 | |||||||||||
cash-flows.row.other-non-cash-items | -2.9 | -0.9 | -0.8 | -0.1 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -19.86 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.2 | -0.1 | |||||||||||
cash-flows.row.acquisitions-net | -3.55 | -3.5 | 0 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 16.68 | 16.7 | 19.8 | 13.2 | |||||||||||
cash-flows.row.other-investing-activites | 0.67 | 0 | 0.3 | 0.4 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 13.8 | 13.1 | 19.9 | 13.4 | |||||||||||
cash-flows.row.debt-repayment | -0.17 | -0.2 | -0.2 | -0.2 | |||||||||||
cash-flows.row.common-stock-issued | 5.86 | 5.7 | 1.5 | 0.6 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | -0.93 | -0.9 | -0.2 | 1.1 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 5.46 | 5.5 | 1.1 | 1.5 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.05 | 0.1 | -0.2 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | -0.54 | -0.5 | 4.1 | -0.4 | |||||||||||
cash-flows.row.cash-at-end-of-period | 68.68 | 14.5 | 15 | 10.9 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 69.22 | 15 | 10.9 | 11.2 | |||||||||||
cash-flows.row.operating-cash-flow | -19.86 | -19.2 | -16.7 | -15.1 | |||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.2 | -0.1 | |||||||||||
cash-flows.row.free-cash-flow | -19.86 | -19.2 | -17 | -15.2 |
Income Statement Row
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | -0.9 | -0.3 | |||||||||||
income-statement-row.row.cost-of-revenue | 0.2 | 0.2 | 0.2 | 0.2 | |||||||||||
income-statement-row.row.gross-profit | -0.2 | -0.2 | -1.1 | -0.6 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 17.03 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.operating-expenses | 22.22 | 22.1 | 22.6 | 17.9 | |||||||||||
income-statement-row.row.cost-and-expenses | 22.27 | 22.3 | 22.6 | 17.9 | |||||||||||
income-statement-row.row.interest-income | 0.47 | 0.5 | 1 | 0.3 | |||||||||||
income-statement-row.row.interest-expense | 2.19 | 2.2 | 0.1 | 0.2 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -7.98 | 2.3 | 0.8 | 0.1 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.total-operating-expenses | -7.98 | 2.3 | 0.8 | 0.1 | |||||||||||
income-statement-row.row.interest-expense | 2.19 | 2.2 | 0.1 | 0.2 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 0.47 | 0.2 | 1.2 | 0.6 | |||||||||||
income-statement-row.row.ebitda-caps | -20.96 | - | - | - | |||||||||||
income-statement-row.row.operating-income | -12 | -22.3 | -22.6 | -17.9 | |||||||||||
income-statement-row.row.income-before-tax | -19.98 | -20 | -21.8 | -17.8 | |||||||||||
income-statement-row.row.income-tax-expense | -9.54 | -0.1 | -0.9 | 0.6 | |||||||||||
income-statement-row.row.net-income | -19.88 | -19.9 | -20.8 | -18.5 |
Frequently Asked Question
What is Purple Biotech Ltd. (PPBT) total assets?
Purple Biotech Ltd. (PPBT) total assets is 44302000.000.
What is enterprise annual revenue?
The annual revenue is N/A.
What is firm profit margin?
Firm profit margin is 0.000.
What is company free cash flow?
The free cash flow is -0.807.
What is enterprise net profit margin?
The net profit margin is 0.000.
What is firm total revenue?
The total revenue is 0.000.
What is Purple Biotech Ltd. (PPBT) net profit (net income)?
The net profit (net income) is -19880000.000.
What is firm total debt?
The total debt is 351000.000.
What is operating expences number?
The operating expences are 22072000.000.
What is company cash figure?
Enretprise cash is 14489000.000.